NO20051339L - Use of lkB kinase inhibitors in the treatment of pain. - Google Patents

Use of lkB kinase inhibitors in the treatment of pain.

Info

Publication number
NO20051339L
NO20051339L NO20051339A NO20051339A NO20051339L NO 20051339 L NO20051339 L NO 20051339L NO 20051339 A NO20051339 A NO 20051339A NO 20051339 A NO20051339 A NO 20051339A NO 20051339 L NO20051339 L NO 20051339L
Authority
NO
Norway
Prior art keywords
pain
treatment
kinase inhibitors
lkb
lkb kinase
Prior art date
Application number
NO20051339A
Other languages
Norwegian (no)
Other versions
NO334309B1 (en
Inventor
Karl Rudolphi
Gerhard Jaehne
Olaf Ritzeler
Martin Michaelis
Gerd Geisslinger
Hans Schaible
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20051339L publication Critical patent/NO20051339L/en
Publication of NO334309B1 publication Critical patent/NO334309B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Det beskrives anvendelse av IkB-kinase-inhibitorer som er egnet for fremstilling av medikamenter for behandling av smerte. Egnede inhibitorer fremstilles fra forbindelsene med formel (I) og (Ia) der substituentene har de angitte betydninger.There is disclosed the use of IkB kinase inhibitors suitable for the preparation of drugs for the treatment of pain. Suitable inhibitors are prepared from the compounds of formula (I) and (Ia) where the substituents have the meanings given.

NO20051339A 2002-08-17 2005-03-15 Use of lkB kinase inhibitors in pain therapy NO334309B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (en) 2002-08-17 2002-08-17 Use of IKappaB kinase inhibitors in pain therapy
PCT/EP2003/008628 WO2004022057A1 (en) 2002-08-17 2003-08-05 USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN

Publications (2)

Publication Number Publication Date
NO20051339L true NO20051339L (en) 2005-05-03
NO334309B1 NO334309B1 (en) 2014-02-03

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051339A NO334309B1 (en) 2002-08-17 2005-03-15 Use of lkB kinase inhibitors in pain therapy

Country Status (34)

Country Link
EP (1) EP1531819B1 (en)
JP (1) JP4504811B2 (en)
KR (2) KR101119845B1 (en)
CN (1) CN100398107C (en)
AR (1) AR043045A1 (en)
AT (1) ATE418336T1 (en)
AU (1) AU2003271555B2 (en)
BR (1) BR0313555A (en)
CA (1) CA2495455C (en)
CO (1) CO5690585A2 (en)
CR (1) CR7716A (en)
CY (1) CY1108874T1 (en)
DE (2) DE10237723A1 (en)
DK (1) DK1531819T3 (en)
EC (1) ECSP055609A (en)
ES (1) ES2320118T3 (en)
HK (1) HK1079426A1 (en)
HR (1) HRP20050041B1 (en)
IL (1) IL166780A (en)
MA (1) MA27334A1 (en)
MX (1) MXPA05001218A (en)
MY (1) MY138059A (en)
NO (1) NO334309B1 (en)
OA (1) OA12907A (en)
PL (1) PL212356B1 (en)
PT (1) PT1531819E (en)
RS (1) RS51878B (en)
RU (1) RU2320338C2 (en)
SI (1) SI1531819T1 (en)
TN (1) TNSN05044A1 (en)
TW (1) TWI325782B (en)
UA (1) UA80837C2 (en)
WO (1) WO2004022057A1 (en)
ZA (1) ZA200500323B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
BRPI0511834A (en) 2004-07-14 2008-01-08 Ptc Therapeutics Inc methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (en) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Process for the preparation of 2- (2-amino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5790440B2 (en) * 2010-12-01 2015-10-07 住友化学株式会社 Pyrimidine compounds and their use for pest control
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2787998B1 (en) * 2011-12-06 2016-11-09 Sanofi Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (en) * 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
CN106535899A (en) * 2014-07-03 2017-03-22 赛诺菲 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
CN112513025A (en) 2018-07-16 2021-03-16 诺华股份有限公司 Chemical process for the preparation of phenylpiperidinylindole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168727C (en) * 1999-06-23 2004-09-29 阿文蒂斯药物德国有限公司 Substituted benzimidazole
DE19951360A1 (en) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
AU2003271555A1 (en) 2004-03-29
AU2003271555B2 (en) 2009-03-26
BR0313555A (en) 2005-07-12
MA27334A1 (en) 2005-05-02
IL166780A (en) 2011-11-30
DK1531819T3 (en) 2009-04-20
CN100398107C (en) 2008-07-02
ECSP055609A (en) 2005-04-18
RS20050070A (en) 2007-06-04
KR20110135428A (en) 2011-12-16
RU2005107419A (en) 2005-08-10
HK1079426A1 (en) 2006-04-07
JP4504811B2 (en) 2010-07-14
JP2005539053A (en) 2005-12-22
UA80837C2 (en) 2007-11-12
AR043045A1 (en) 2005-07-13
CA2495455C (en) 2011-01-11
HRP20050041B1 (en) 2013-07-31
CA2495455A1 (en) 2004-03-18
EP1531819B1 (en) 2008-12-24
DE10237723A1 (en) 2004-07-08
HRP20050041A2 (en) 2006-04-30
KR20050058339A (en) 2005-06-16
ES2320118T3 (en) 2009-05-19
RS51878B (en) 2012-02-29
PL212356B1 (en) 2012-09-28
TWI325782B (en) 2010-06-11
DE50310980D1 (en) 2009-02-05
TNSN05044A1 (en) 2007-05-14
NO334309B1 (en) 2014-02-03
CN1674899A (en) 2005-09-28
IL166780A0 (en) 2006-01-15
KR101119845B1 (en) 2012-02-28
RU2320338C2 (en) 2008-03-27
CO5690585A2 (en) 2006-10-31
CR7716A (en) 2008-11-25
MXPA05001218A (en) 2005-05-16
ZA200500323B (en) 2006-02-22
OA12907A (en) 2006-10-13
MY138059A (en) 2009-04-30
ATE418336T1 (en) 2009-01-15
CY1108874T1 (en) 2014-07-02
SI1531819T1 (en) 2009-06-30
WO2004022057A1 (en) 2004-03-18
EP1531819A1 (en) 2005-05-25
PT1531819E (en) 2009-02-18
TW200417370A (en) 2004-09-16
PL373568A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
NO20051339L (en) Use of lkB kinase inhibitors in the treatment of pain.
NO20050828L (en) indole-3-sulfur derivatives
EA200700099A1 (en) PYRIDINE DERIVATIVES
NO20055421L (en) Quinoline derivatives as phosphodiesterase inhibitors
NO341617B1 (en) Dihydropyrazole pyrimidinone derivatives, their use in therapy and in the treatment of cancer, their use in the manufacture of a medicament, and in use as a radiation sensitizer, their pharmaceutical composition, and a combined preparation for administration in the treatment of cancer.
GB0112348D0 (en) Compounds
MX2007004248A (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors.
NO20051010L (en) Triazole derivatives as transforming growth factor (TGF) inhibitors
NO20056192L (en) Capase inhibitors and their use
MXPA05010958A (en) Indazole derivatives as jnk inhibitors.
MXPA05013349A (en) 2-aminopyrimidine derivatives as raf kinase inhibitors.
UA84175C2 (en) Heterocyclic mek inhibitors and use thereof
NO20073140L (en) Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases
NO20071320L (en) Pyrazole-substituted amino heteroaryl compounds as protein kinase inhibitors.
NO20061839L (en) Benzimidazole derivatives, compositions containing them, their preparation, and their use
NO20073926L (en) Pyrazole compounds that modulate activity of CDK, GSK and aurorakinases
NO20070224L (en) 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof
NO20082496L (en) pyrazine derivatives
NO20090580L (en) Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
NO20085217L (en) Effective pyrimidine derivatives in the treatment of cancer
DE60320012D1 (en) AMINO-ETHEROCYCLES AS VR-1 ANTAGONISTS FOR THE TREATMENT OF PAIN
NO20062583L (en) Diphenyllazetidinone derivatives with cholesterol absorption inhibitory activity
DE602004022668D1 (en) 5-LOW HETEROCYCLIC P-38 INHIBITORS
NO20051008L (en) Novel imidazole compounds as transforming growth factor (TGF) inhibitors
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees